MeSH tree: D03.383.679
Adding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is associated with a lower risk of a major cardiovascular event, such as a heart ...
Aug 5, 2026
0
7
New research has uncovered why one of the most widely used treatments for multiple myeloma can cause debilitating nerve and gastrointestinal side effects, marking a significant step toward preventing them.
Jul 15, 2026
0
3
Obesity is closely intertwined with high blood pressure and diabetes, often putting patients at greater risk for either of these health conditions. It's also associated with arterial stiffening—when the walls of the artery ...
May 13, 2026
0
5
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet how metabolic stress ...
Mar 18, 2026
0
11
A higher dose of the antibiotic rifampicin does not improve survival rates for patients with tuberculous meningitis. This severe form of tuberculosis causes inflammation of the brain membranes, and half of the patients die. ...
Dec 17, 2025
0
13
For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled out diabetes before finally ...
Nov 11, 2025
0
17
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...
Nov 10, 2025
0
49
People diagnosed with multiple myeloma—one of the most common forms of blood cancer—are now living nearly twice as long on average as they were in 2005, according to a new study.
Sep 4, 2025
0
16
Medicines containing a type of PFAS or "forever chemical" called fluorine are not leading to higher numbers of adverse drug reactions, according to new data analysis.
Sep 2, 2025
0
17
Yonsei University College of Medicine-led research has shown amiloride is as effective as spironolactone in reducing systolic blood pressure (SBP) over 12 weeks in patients with resistant hypertension.
